Skip to main content

Advertisement

SpringerLink
Log in

The Rapidly Evolving Research on Vitamin D Among HIV-Infected Populations

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

With ongoing improvement in antiretroviral therapy, mortality among HIV-infected persons has dramatically decreased. For HIV-infected persons who remain engaged in care on suppressive therapy, life expectancy approaches that of the general population. Additionally, we have seen increases in comorbidities traditionally associated with aging: diabetes, hypertension, dyslipidemia, ischemic heart disease, and osteoporosis. Vitamin D deficiency has also been identified as a highly prevalent entity among HIV-infected populations. The association of vitamin D deficiency with several of these comorbidities and its impact on immune function provide the impetus for well-designed studies to evaluate the impact of vitamin D supplementation on HIV disease and antiretroviral therapy. This review summarizes the role of vitamin D in several disease states that are prevalent among HIV populations, with a specific focus on bone health and the interactions with antiretroviral medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Palella FJ, Baker RK, Moorman AC, et al.: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006 Sep;43(1):27–34.

    Article  CAS  PubMed  Google Scholar 

  2. Lampe FC, Smith CJ, Madge S, et al.: Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med. 2007 Apr 9;167(7):692–700.

    Article  PubMed  Google Scholar 

  3. Bhavan KP, Kampalath VN, Overton ET: The aging of the HIV epidemic. Curr HIV/AIDS Rep. 2008;5(3):150–158.

    Article  PubMed  Google Scholar 

  4. Tebas P, Powderly WG, Claxton S, et al.: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63–F67.

    Article  CAS  PubMed  Google Scholar 

  5. Brown TT, Qaqish RB: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165–2174.

    Article  PubMed  Google Scholar 

  6. • Triant VA, Brown TT, Lee H, Grinspoon SK: Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008 Sep;93(9):3499–3504. This article is the first research paper to illustrate that the low bone mineral density among HIV-infected persons leads to fragility fractures.

    Article  CAS  PubMed  Google Scholar 

  7. • McComsey GA, Tebas P, Shane E, et al.: Bone Disease in HIV: A Practical Review and Recommendations for HIV Providers. CID. 2010;51:937–946. This article is a recent review of issues related to bone health for HIV care providers.

    Article  Google Scholar 

  8. Hess AF, Unger LF: The cure of infantile rickets by sunlight. JAMA. 1921;77(1):39–41.

    Google Scholar 

  9. Chalmers J, Conacher WDH, Garnder DL, Scott PJ: Osteomalacia: a common disease in elderly women. J Bone Joint Surg Br. 1967;49(3):403–423.

    CAS  PubMed  Google Scholar 

  10. Holick MF: Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281.

    Article  CAS  PubMed  Google Scholar 

  11. Heaney RP: The case for improving vitamin D status. J Steroid Biochem Mol Biol 2007;103(3–5):635–641.

    Article  CAS  PubMed  Google Scholar 

  12. Lips P, Duong T, Oleksik A, et al.: A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab. 2001;86:1212–1221.

    Article  CAS  PubMed  Google Scholar 

  13. Holick MF: Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006;116:2062–2072.

    Article  CAS  PubMed  Google Scholar 

  14. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670–676.

    Article  CAS  PubMed  Google Scholar 

  15. Holick MF: High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006 Mar;81(3):353–373.

    Article  CAS  PubMed  Google Scholar 

  16. Broe KE, Chen TC, Weinberg J, et al.: A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J Am Geriatr Soc. 2007 Feb;55(2):234–239.

    Article  PubMed  Google Scholar 

  17. Gloth FM III, Alam W, Hollis B: Vitamin D vs. broad spectrum phototherapy in the treatment of seasonal effective disorder. J Nutr Health Aging 1999;3:5–7.

    PubMed  Google Scholar 

  18. Wilkins CH, Birge SJ, Sheline YI, Morris JC: Vitamin D deficiency is associated with worse cognitive performance and lower bone density in older African Americans. J Natl Med Assoc. 2009 Apr;101(4):349–354.

    PubMed  Google Scholar 

  19. Evatt ML, Delong MR, Khazai N, et al.: Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008 Oct;65(10):1348–1352.

    Article  PubMed  Google Scholar 

  20. Pittas AG, Lau J, Hu FB, Dawson-Hughes B: The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007 Jun;92(6):2017–2029.

    Article  CAS  PubMed  Google Scholar 

  21. Johnson JA, Grande JP, Roche PC, Kumar R: Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol. 1994;267:E356–E360.

    CAS  PubMed  Google Scholar 

  22. Bland R, Markovic D, Hills CE, et al.: Expression of 25-hydroxyvitamin D3–1-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol. 2004;89–90:121–125.

    Article  PubMed  Google Scholar 

  23. Hypponen E, Laara E, Reunanen A, et al.: Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500–1503.

    Article  CAS  PubMed  Google Scholar 

  24. Orwoll E, Riddle M, Prince M: Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 1994;59:1083–1087.

    CAS  PubMed  Google Scholar 

  25. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B: The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in non-diabetic adults. Diabetes Care. 2007;30:980–986.

    Article  CAS  PubMed  Google Scholar 

  26. Pittas AG, Dawson-Hughes B, Li T, et al.: Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006;29:650–656.

    Article  CAS  PubMed  Google Scholar 

  27. Zittermann A: Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006;92:39–48.

    Article  CAS  PubMed  Google Scholar 

  28. Pérez-López FR: Vitamin D metabolism and cardiovascular risk factors in postmenopausal women. Maturitas. 2009 Mar 20;62(3):248–262.

    Article  PubMed  Google Scholar 

  29. Heaney R, Dowell M, Hale C, Bendich A: Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J. Am. Coll. Nutr. 2003;22:142–146.

    CAS  PubMed  Google Scholar 

  30. Li YC: Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003;88:327–331.

    Article  CAS  PubMed  Google Scholar 

  31. Rostand SG: Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997;30:150–156.

    CAS  PubMed  Google Scholar 

  32. Krause R, Buhring M, Hopfenmuller W, et al.: Ultraviolet B and blood pressure. Lancet 1998;352:709–710.

    Article  CAS  PubMed  Google Scholar 

  33. Giovannucci E, Liu Y, Rimm EB, et al.: Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006;98:451–459.

    Article  CAS  PubMed  Google Scholar 

  34. Deluca HF, Cantorna MT: Vitamin D: its role and uses in immunology. FASEB J. 2001 Dec;15(14):2579–2585.

    Article  CAS  PubMed  Google Scholar 

  35. Cantorna MT, Zhu Y, Froicu M, Wittke A: Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004;80:Suppl 6:1717S–1720S.

    CAS  PubMed  Google Scholar 

  36. Cantorna MT, Hullett DA, Redaelli C, et al.: 1,25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. Transplantation. 1998 Oct 15;66(7):828–831.

    Article  CAS  PubMed  Google Scholar 

  37. Bodnar LM, Simhan HN, Powers RW, et al.: High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. J Nutr 2007;137(2):447–452

    CAS  PubMed  Google Scholar 

  38. Gordon CM, DePeter KC, Feldman HA, et al.: Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004;158:531–537.

    Article  PubMed  Google Scholar 

  39. Ginde AA, Liu MC, Camaargo CA: Demographic Differences and Trends of Vitamin D Insifficiency in the US Population, 1988–2004. Arch Intern Med. 2009; 626–632.

  40. Guaraldi G, Orlando G, Squillace N, et al.: Prevalence of secondary causes of osteoporosis among HIV-infected individuals, Antiviral Therapy. 2006; 11(7):L9.

    Google Scholar 

  41. Rodríguez M, Daniels B, Gunawardene S, Robbins GK: High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses. 2009 Jan;25(1):9–14.

    Article  PubMed  Google Scholar 

  42. • Dao CN, Patel P, Overton ET, et al., and the Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN) Investigators: Prevalence of and risk factors for low levels of vitamin D in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis, in press. This article provides recent data comparing vitamin D levels among HIV-infected and HIV-negative persons in the United States.

  43. • Stein EM, Yin MT, McMahon DJ, et al.: Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int 2010 (Epub ahead of print). This article provides recent data highlighting the epidemic of vitamin D deficiency among postmenopausal women in the United States.

  44. Yin MT, Lu D, Cremers S, et al.: Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr. 2010 Feb 1;53(2):202–208.

    Article  PubMed  Google Scholar 

  45. Bang UC, Shakar SA, Hitz MF, et al.: Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study. Scand J Infect Dis. 2010 Apr;42(4):306–310.

    Article  CAS  PubMed  Google Scholar 

  46. Borderi M, Vescini F, Cozzi-Lepri A, et al.: 2010 Prevalence of hypovitaminosis D among HIV + patients enrolled in a large Italian cohort. Presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 16–19, 2010.

  47. Mueller NJ, Fux CA, Ledergerber B, et al.: High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010 May 15;24(8):1127–1134.

    Article  CAS  PubMed  Google Scholar 

  48. Welz T, Childs K, Ibrahim F, et al.: Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010 Jul 31;24(12):1923–1928.

    Article  CAS  PubMed  Google Scholar 

  49. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al.: Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008 Nov;24(11):1375–1382.

  50. Christakos S, Ajibade DV, Dhawan P, et al.: Vitamin D: metabolism. Endocrinol Metab Clin North Am. 2010 Jun;39(2):243–253.

    Article  CAS  PubMed  Google Scholar 

  51. Madeddu G, Spanu A, Solinas P, et al.: Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004; 48(1):39–48.

    PubMed  Google Scholar 

  52. Fernandez-Rivera J, Garcia R, Lozano F, et al.: Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003; 4(5):337–346.

    Article  CAS  PubMed  Google Scholar 

  53. McComsey GA, Kitch D, Daar E, et al.: Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection [abstract 106LB]. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections February 16–19, 2010, San Francisco, CA.

  54. Duvivier C, Kolta S, Assoumou L, et al.: Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23(7):817–824.

    Article  PubMed  Google Scholar 

  55. Cozzolino M, Vidal M, Vittoria Arcidiacono M, et al.: HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003; 17:513–520.

    Article  CAS  PubMed  Google Scholar 

  56. Gyllensten K, Josephson F, Lidman K, Saaf M: Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59N. AIDS 2006; 20(14):1906–1907.

    Article  PubMed  Google Scholar 

  57. Fabbriciani G, De Socio GV: Efavirenz and bone health. AIDS 2009; 23(9):1181.

    Article  PubMed  Google Scholar 

  58. Herzmann C, Arasteh K: Efavirenz-induced osteomalacia. AIDS 2009; 23(2):274–275.

    Article  PubMed  Google Scholar 

  59. • Brown TT, McComsey GA: Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15(3):425–429. The authors highlight the impact of various antiretroviral agents on vitamin D metabolism.

    Article  CAS  PubMed  Google Scholar 

  60. Welz T, Childs K, Ibrahim F, et al.: Efavirenz use is associated with severe vitamin D deficiency in a large, ethnically diverse urban UK HIV cohort. Program and Abstracts of 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa; 2009.

  61. Fox J, Peters B, Prakash M, et al.: Improvement in vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res Hum Retroviruses. 2010 (Epub ahead of print).

  62. Valsamis HA, Arora SK, Labban B, McFarlane SI: Antiepileptic drugs and bone metabolism. Nutr Metab (Lond) 2006; 3:36.

    Article  Google Scholar 

  63. Pascussi JM, Robert A, Nguyen M, et al.: Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115:177–186.

    CAS  PubMed  Google Scholar 

  64. Lattuada E, Lanzafame M, Zoppini G, et al.: No influence of nevirapine on vitamin D deficiency in HIV-infected patients. AIDS Research and Human Retroviruses 2009; 25(8):849–850.

    Article  CAS  PubMed  Google Scholar 

  65. Cervero M, Alcazar V, Garcia-LaCalle C, et al.: Prevalence of vitamin D deficiency in HIV infection. Abstract H-230. ICAAC 2010; Boston, MA.

  66. Pasquet A, Viget N, Choisy P, et al.: Prevalence and risk factors for hypovitaminosis D among HIV-infected patients in a French HIV Clinical Cohort. Abstracts H-225. ICAAC 2010; Boston, MA.

  67. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naive patients: a 3-year randomized trial. JAMA. 2004; 292(2):191–201.

    Article  CAS  PubMed  Google Scholar 

  68. Cooper DA, Bloch M, Humphries A, et al.: Simplification with fixed dose tenofovir-emtricitaine or abacavir-lamivudine in adults with suppressed HIV repliation (The Steal Study): A randomized, open-label, 96-week, non-inferiority trial [abstract 576]. In Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections February 8–11, 2009, Montreal, Canada.

  69. Labarga P, Barreiro P, Martin-Carbonero L, et al.: Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009 Mar 27;23(6):689–696.

    Article  CAS  PubMed  Google Scholar 

  70. Fux CA, Rauch A, Simcock M, et al.: Swiss HIV Cohort Study. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther. 2008;13(8):1077–1082.

    CAS  Google Scholar 

  71. Rosenvinge MM, Gedela K, Copas AJ, et al.: Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010 Aug 15;54(5):496–499.

    Article  CAS  PubMed  Google Scholar 

  72. Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA: Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf). 1995;43(4):479–490.

    Article  CAS  Google Scholar 

  73. Overton ET, Mondy K, Bush T, et al.: Factors Associated with Low Bone Mineral Density in a Large Cohort of HIV-infected US Adults: Baseline Results from the SUN Study. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections 2007. Los Angeles, CA: Abstract 836.

  74. Arnsten JH, Freeman R, Howard AA, et al.: Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21(5):617–623.

    Article  PubMed  Google Scholar 

  75. Dao C, Young B, Buchacz K, et al., and the HIV Outpatient Study Investigators: Higher and Increasing Rates of Fracture among HIV-infected Persons in the HIV Outpatient Study Compared to the General US Population, 1994 to 2008. Abstract 128. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections February 16–19, 2010, San Francisco, CA.

  76. Womack J, Goulet J, Gibert C, et al., and Veterans Aging Cohort Project Team: HIV-Infection and Fragility Fracture Risk among Male Veterans. Abstract 129. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections February 16–19, 2010, San Francisco, CA.

  77. Tebas P, Umbleja T, Dubé M, et al.: Initiation of ART Is Associated with Bone Loss Independent of the Specific ART Regimen. The Results of ACTG A5005s Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections 2007. Los Angeles, CA: Abstract 837.

  78. • Grund B, Peng G, Gibert CL, et al.; INSIGHT SMART Body Composition Substudy Group: Continuous antiretroviral therapy (ART) decreases bone mineral density. AIDS. 2009 Jul 31;23(12):1519–1529. This article provides data from the SMART study highlighting the negative impact of cART on bone health.

    Article  CAS  PubMed  Google Scholar 

  79. Mondy K, Powderly WG, Claxton SA, et al.: Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38(4):426–431.

    Article  CAS  PubMed  Google Scholar 

  80. McComsey GA, Kendall MA, Tebas P, et al.: Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21(18):2473–2482.

    Article  CAS  PubMed  Google Scholar 

  81. Schneider JP: Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics. 2009 Jan;64(1):18–23.

    PubMed  Google Scholar 

  82. Strampel W, Emkey R, Civitelli R: Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf. 2007;30(9):755–763.

    Article  CAS  PubMed  Google Scholar 

  83. Shane E, Burr D, Ebeling PR, et al.: Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010 (Epub ahead of print).

  84. Buitrago C, Boland R, de Boland AR: The tyrosine kinase c-Src is required for 1,25(OH)2-vitamin D3 signalling to the nucleus in muscle cells. Biochim Biophys Acta. 2001 Dec 19;1541(3):179–187.

    Article  CAS  PubMed  Google Scholar 

  85. Buitrago C, Vazquez G, De Boland AR, Boland R: The vitamin D receptor mediates rapid changes in muscle protein tyrosine phosphorylation induced by 1,25(OH)(2)D(3). Biochem Biophys Res Commun. 2001 Dec 21;289(5):1150–1156.

    Article  CAS  PubMed  Google Scholar 

  86. Kumar V, Mukhopadhyay S, Singh Bedi P, et al.: A novel modulatory role of vitamin D3 in exercise-induced apoptosis of rat skeletal muscle. Am J Food Technol 2008; 3: 361–372.

    Article  CAS  Google Scholar 

  87. Boland R: Role of vitamin D in skeletal muscle function. Endocr Rev. 1986 Nov;7(4):434–448.

    Article  CAS  PubMed  Google Scholar 

  88. Yoshikawa S, Nakamura T, Tanabe H, Imamura T: Osteomalacic myopathy. Endocrinol Jpn. 1979 Jun;26(Suppl):65–72.

    CAS  PubMed  Google Scholar 

  89. Sato Y, Iwamoto J, Kanoko T, Satoh K: Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis. 2005;20(3):187–92.

    Article  CAS  PubMed  Google Scholar 

  90. • Ceglia L: Vitamin D and its role in skeletal muscle. Curr Opin Clin Nutr Metab Care. 2009 Nov;12(6):628–633. This article provides a comprehensive review of effects of vitamin D on muscle health.

    Article  CAS  PubMed  Google Scholar 

  91. Dam TT, von Mühlen D, Barrett-Connor EL: Sex-specific association of serum vitamin D levels with physical function in older adults. Osteoporos Int. 2009 May;20(5):751–760.

    Article  CAS  PubMed  Google Scholar 

  92. Kuchuk NO, Pluijm SM, van Schoor NM, et al.: Relationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older persons. J Clin Endocrinol Metab. 2009 Apr;94(4):1244–1250.

    Article  PubMed  Google Scholar 

  93. El-Hajj Fuleihan G, Nabulsi M, Tamim H, et al.: Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab. 2006 Feb;91(2):405–412.

    Article  PubMed  Google Scholar 

  94. Bischoff HA, Stähelin HB, Dick W, et al.: Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res. 2003 Feb;18(2):343–351.

    Article  CAS  PubMed  Google Scholar 

  95. Pfeifer M, Begerow B, Minne HW, et al.: Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2009 Feb;20(2):315–322.

    Article  CAS  PubMed  Google Scholar 

  96. Bischoff-Ferrari HA, Willett WC, Wong JB, et al.: Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005 May 11;293(18):2257–2264.

    Article  CAS  PubMed  Google Scholar 

  97. Brown TT, Cole SR, Li X, et al.: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–1184.

    Article  PubMed  Google Scholar 

  98. Justman JE, Benning L, Danoff A, et al.: Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298–302.

    Article  CAS  PubMed  Google Scholar 

  99. Tebas P: Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 2:S86–S92.

    CAS  PubMed  Google Scholar 

  100. Rosen CJ, Klibanski A: Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med. 2009 May;122(5):409–414.

    Article  CAS  PubMed  Google Scholar 

  101. Hamrick MW, Ferrari SL: Leptin and the sympathetic connection of fat to bone. Osteoporos Int. 2008 Jul;19(7):905–912.

    Article  CAS  PubMed  Google Scholar 

  102. Ducy P, Amling M, Takeda S, et al.: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000 Jan 21;100(2):197–207.

    Article  CAS  PubMed  Google Scholar 

  103. Lee NK, Sowa H, Hinoi E, et al.: Endocrine regulation of energy metabolism by the skeleton. Cell. 2007 Aug 10;130(3):456–469.

    Article  CAS  PubMed  Google Scholar 

  104. Mathieu C, Casteels K, Waer M, et al.: Prevention of diabetes recurrence after syngeneic islet transplantation in NOD mice by analogues of 1,25(OH)2D3 in combination with cyclosporin A: mechanism of action involves an immune shift from Th1 to Th2. Transplant Proc. 1998 Mar;30(2):541.

    Article  CAS  PubMed  Google Scholar 

  105. Jamieson BD, Douek DC, Killian S, et al.: Generation of functional thymocytes in the human adult. Immunity 1999;10:569–575.

    Article  CAS  PubMed  Google Scholar 

  106. Aldrovandi GM, Feuer G, Gao L, et al.: The SCID-hu mouse as a model for HIV-1 infection. Nature 1993;363:732–736.

    Article  CAS  PubMed  Google Scholar 

  107. Appay V, Rowland-Jones SL: Premature ageing of the immune system: the cause of AIDS? Trends in Immunology 2002; 23 (12): 580–585.

    Article  CAS  PubMed  Google Scholar 

  108. Luciano AA, Lederman MM, Valentin-Torres A, et al.: Impaired induction of CD27 and CD28 predicts naïve CD4 T cell proliferation defects in HIV disease. J Immunol. 2007; 179 (6): 3543–3549.

    CAS  PubMed  Google Scholar 

  109. Arpadi SM, McMahon D, Abrams EJ, et al.: Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics. 2009 Jan;123(1):e121-6. Erratum in: Pediatrics. 2009 May;123(5):1437.

    Article  PubMed  Google Scholar 

  110. Mehta S, Giovannucci E, Mugusi FM, et al.: Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One. 2010 Jan 19;5(1):e8770.

    Article  PubMed  Google Scholar 

  111. Mehta S, Hunter DJ, Mugusi FM, et al.: Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. J Infect Dis. 2009 Oct 1;200(7):1022–1030.

    Article  CAS  PubMed  Google Scholar 

  112. European AIDS Clinical Society: Guidelines: prevention and management of non-infectious co-morbidities in HIV. Available at http://www.europeanaidsclinicalsociety.org/guidelinespdf/2_Non_Infectious_Co_Morbidities_in_HIV.pdf. Accessed September 2010.

  113. Aberg JA, Kaplan JE, Libman H, et al.; HIV Medicine Association of the Infectious Diseases Society of America: Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009 Sep 1;49(5):651–681.

    Article  PubMed  Google Scholar 

  114. Holick MF: Vitamin D: Evolutionary, physiological and health perspectives. Curr Drug Targets 2010 (Epub ahead of print).

  115. Heaney RP: Vitamin D: criteria for safety and efficacy. Nutr Rev. 2008 Oct;66(10 Suppl 2):S178–S181.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Conflicts of interest: E. Overton—grants from the Centers for Disease Control and Prevention, National Institutes of Health, GlaxoSmithKline, Tibotec, and Gilead, and honoraria from Boehringer Ingelheim, Bristol-Meyers Squibb, GlaxoSmithKline/Viiv, Tibotec, Gilead, Merck, and Monogram Sciences; M. Yin—grants from the National Institutes of Health, Gilead, and Bristol-Meyers Squibb, and honoraria from Gilead.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Washington University School of Medicine, Campus Box 8011, 660 South Euclid Avenue, St. Louis, MO, 63110, USA

    Edgar Turner Overton

  2. Division of Infectious Diseases, Columbia University Medical Center, PH8-876, 630 West 168th Street, New York, NY, USA

    Michael T. Yin

Authors
  1. Edgar Turner Overton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael T. Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edgar Turner Overton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Overton, E.T., Yin, M.T. The Rapidly Evolving Research on Vitamin D Among HIV-Infected Populations. Curr Infect Dis Rep 13, 83–93 (2011). https://doi.org/10.1007/s11908-010-0144-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-010-0144-x

Keywords

Search

Navigation